Lista de obras - Georg A. Bjarnason - Dominio Público Uruguay

A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer

artículo científico publicado en 2008

A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma

artículo científico publicado en 2006

A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.

artículo científico publicado en 2013

Are medical oncologists biased in their treatment of the large woman with breast cancer?

artículo científico publicado en 2001

Canadian guideline on genetic screening for hereditary renal cell cancers

artículo científico publicado en 2013

Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium

artículo científico publicado en 2014

Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.

artículo científico publicado en 2014

Chronobiology. Implications for cancer chemotherapy.

artículo científico publicado en 1995

Chronotherapy and the molecular clock: Clinical implications in oncology.

scientific article published on 23 June 2010

Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer

artículo científico publicado en 2009

Circadian variation in the expression of cell-cycle proteins in human oral epithelium

artículo científico publicado en 1999

Clinical cancer chronotherapy trials: a review

artículo científico publicado el 1 de enero de 1995

Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3).

artículo científico publicado en 2008

Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.

artículo científico publicado en 2012

Could time of whole brain radiotherapy delivery impact overall survival in patients with multiple brain metastases?

artículo científico publicado en 2016

Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

artículo científico publicado en 2014

Diurnal protein expression in blood revealed by high throughput mass spectrometry proteomics and implications for translational medicine and body time of day.

artículo científico publicado en 2007

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.

artículo científico

Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy.

artículo científico publicado en 2011

Effects of circadian rhythms and treatment times on the response of radiotherapy for painful bone metastases.

artículo científico publicado en 2016

Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.

artículo científico publicado en 2014

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

artículo científico publicado en 2013

Exploring the role of miRNAs in renal cell carcinoma progression and metastasis through bioinformatic and experimental analyses.

artículo científico publicado en 2011

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

artículo científico publicado en 2013

Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer

artículo científico publicado en 2013

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC.

artículo científico publicado en 2014

Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis

scientific article published on 04 February 2014

Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy

artículo científico publicado en 2013

Improved flow measurement using microbubble contrast agents and disruption-replenishment: clinical application to tumour monitoring

artículo científico publicado en 2011

Irinotecan-associated pulmonary toxicity

scientific article published on 01 October 2000

It is time for chronotherapy!

artículo científico publicado en 2003

Menstrual cycle chronobiology: is it important in breast cancer screening and therapy?

scientific article published on 01 February 1996

Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

artículo científico publicado en 2014

Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature

artículo científico publicado en 2013

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.

artículo científico publicado en 2014

Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma.

artículo científico publicado en 1999

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

artículo científico publicado en 2009

Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients

scientific article published on 01 January 1993

Phase I study of 5-fluorouracil and leucovorin by continuous infusion chronotherapy and pelvic radiotherapy in patients with locally advanced or recurrent rectal cancer

artículo científico publicado en 2004

Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer

artículo científico publicado en 1998

Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer.

artículo científico publicado en 2012

Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group

artículo científico publicado en 2003

Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment

scientific article published on 01 August 2006

Postoperative concurrent chronomodulated 5-fluorouracil/leucovorin infusion and pelvic radiotherapy for squamous cell carcinoma of the ovary arising from mature cystic teratoma

artículo científico publicado en 2001

Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer.

artículo científico publicado en 2012

Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963).

artículo científico publicado en 2011

Preoperative stereotactic body radiotherapy to a skull renal cell metastasis: an alternative to preoperative embolization?

artículo científico publicado en 2011

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

artículo científico publicado en 2011

Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.

artículo científico publicado en 2010

Quantifying vascular heterogeneity using microbubble disruption-replenishment kinetics in patients with renal cell cancer.

artículo científico publicado en 2014

Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance

artículo científico publicado en 2012

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

artículo científico publicado en 2013

Rhythms in human gastrointestinal mucosa and skin.

artículo científico publicado en 2002

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

artículo científico publicado en 2009

Scoring oral mucositis

scientific article published on 01 January 1998

Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis.

artículo científico publicado en 2012

Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture

artículo científico publicado en 2014

Steroid-responsive interstitial lung disease in patients receiving 2'-deoxy-5-fluorouridine-infusion chemotherapy. A report of three cases.

artículo científico publicado en 1995

Subjective sleep and overall survival in chemotherapy-naïve patients with metastatic colorectal cancer

artículo científico publicado en 2015

Sunitinib in metastatic renal cell carcinoma patients with brain metastases.

artículo científico publicado en 2010

Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.

artículo científico publicado en 2011

Survey of consecutive prostate cancer patients attending the Toronto Sunnybrook Regional Cancer Centre (TSRCC)

artículo científico publicado el 1 de noviembre de 1996

Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.

artículo científico publicado en 2013

Systemic therapy in metastatic renal cell carcinoma: Emerging challenges in therapeutic choice

artículo científico publicado en 2020

The Clinical Utility of miR-21 as a Diagnostic and Prognostic Marker for Renal Cell Carcinoma

artículo científico publicado en 2012

The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study

artículo científico publicado en 2015

The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial

artículo científico publicado en 2019

The emerging roles of stereotactic ablative radiotherapy for metastatic renal cell carcinoma

artículo científico

Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Researc

artículo científico publicado en 2008

miR-210 is a prognostic marker in clear cell renal cell carcinoma

artículo científico publicado en 2014

miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation.

artículo científico publicado en 2011

miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215

artículo científico publicado en 2011

Lista de obras de Georg A. Bjarnason

A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer

A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma

A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.

Are medical oncologists biased in their treatment of the large woman with breast cancer?

Canadian guideline on genetic screening for hereditary renal cell cancers

Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium

Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.

Chronobiology. Implications for cancer chemotherapy.

Chronotherapy and the molecular clock: Clinical implications in oncology.

Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer

Circadian variation in the expression of cell-cycle proteins in human oral epithelium

Clinical cancer chronotherapy trials: a review

Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3).

Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.

Could time of whole brain radiotherapy delivery impact overall survival in patients with multiple brain metastases?

Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Diurnal protein expression in blood revealed by high throughput mass spectrometry proteomics and implications for translational medicine and body time of day.

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.

Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy.

Effects of circadian rhythms and treatment times on the response of radiotherapy for painful bone metastases.

Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

Exploring the role of miRNAs in renal cell carcinoma progression and metastasis through bioinformatic and experimental analyses.

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC.

Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis

Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy

Improved flow measurement using microbubble contrast agents and disruption-replenishment: clinical application to tumour monitoring

Irinotecan-associated pulmonary toxicity

It is time for chronotherapy!

Menstrual cycle chronobiology: is it important in breast cancer screening and therapy?

Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.

Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma.

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients

Phase I study of 5-fluorouracil and leucovorin by continuous infusion chronotherapy and pelvic radiotherapy in patients with locally advanced or recurrent rectal cancer

Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer

Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer.

Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group

Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment

Postoperative concurrent chronomodulated 5-fluorouracil/leucovorin infusion and pelvic radiotherapy for squamous cell carcinoma of the ovary arising from mature cystic teratoma

Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer.

Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963).

Preoperative stereotactic body radiotherapy to a skull renal cell metastasis: an alternative to preoperative embolization?

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.

Quantifying vascular heterogeneity using microbubble disruption-replenishment kinetics in patients with renal cell cancer.

Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

Rhythms in human gastrointestinal mucosa and skin.

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

Scoring oral mucositis

Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis.

Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture

Steroid-responsive interstitial lung disease in patients receiving 2'-deoxy-5-fluorouridine-infusion chemotherapy. A report of three cases.

Subjective sleep and overall survival in chemotherapy-naïve patients with metastatic colorectal cancer

Sunitinib in metastatic renal cell carcinoma patients with brain metastases.

Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.

Survey of consecutive prostate cancer patients attending the Toronto Sunnybrook Regional Cancer Centre (TSRCC)

Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.

Systemic therapy in metastatic renal cell carcinoma: Emerging challenges in therapeutic choice

The Clinical Utility of miR-21 as a Diagnostic and Prognostic Marker for Renal Cell Carcinoma

The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study

The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial

The emerging roles of stereotactic ablative radiotherapy for metastatic renal cell carcinoma

Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Researc

miR-210 is a prognostic marker in clear cell renal cell carcinoma

miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation.

miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215